Interestingly, GBM organoids cultured in engineered hydrogels with low HA content were approximately three times more sensitive to anti‐tumor drugs than that in stiffness‐matched matrices with high HA content, and knockout of CD44 could counteract this resistant phenotype. This evidence concerns the gene CD44 and glioblastoma.